Reeve J G, Rabbitts P H, Twentyman P R
MRC Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre, Cambridge, UK.
Br J Cancer. 1989 Sep;60(3):339-42. doi: 10.1038/bjc.1989.282.
Amplification and expression of the mdr1 gene encoding P-glycoprotein have been studied in H69/LX4 a multidrug resistant variant (MDR) of small cell lung cancer (SCLC) cell line NCI-H69. Recently a second independently derived MDR variant of this cell line designated H69/AR was found by others not to show amplification, rearrangement or over-expression of the mdr1 gene. The present study reports that in marked contrast to H69/AR, H69/LX4 shows amplification and expression of the P-glycoprotein gene and raises the possibility that P-glycoprotein hyperexpression may be a clinically relevant component of MDR in some SCLC tumours.
编码P-糖蛋白的mdr1基因的扩增和表达已在小细胞肺癌(SCLC)细胞系NCI-H69的多药耐药变体(MDR)H69/LX4中进行了研究。最近,其他人发现该细胞系的第二个独立衍生的MDR变体H69/AR未显示mdr1基因的扩增、重排或过表达。本研究报告称,与H69/AR形成显著对比的是,H69/LX4显示P-糖蛋白基因的扩增和表达,并提出P-糖蛋白过表达可能是某些SCLC肿瘤中MDR的临床相关组成部分的可能性。